Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 4/20 | 0.46 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.46 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3631276 | 0.84 | DRD2 (0.42) | HRH3METKCNA5ACHE | |
| SCHEMBL3498232 | 0.73 | NPC1 (0.42) | HRH3METACHE | |
| SCHEMBL5075071 | 0.72 | HRH3 (0.56) | HRH3 | |
| SCHEMBL10025500 | 0.69 | FGFR1 (0.54) | TGFBR1MAP3K20LMNAMAPTHPGD | |
| SCHEMBL18731432 | 0.68 | TGFBR1 (0.51) | TGFBR1MAP3K20TGFBR2LMNAMAPT | |
| SCHEMBL24445448 | 0.68 | CYP2D6 (0.49) | MAPTHRH3 | |
| SCHEMBL1623491 | 0.68 | NPC1 (0.53) | HRH3MET | |
| SCHEMBL16523574 | 0.67 | ACHE (0.66) | HRH3ACHE | |
| SCHEMBL29832319 | 0.66 | DRD2 (0.71) | LMNAMAPTHPGD | |
| SCHEMBL17678285 | 0.66 | DRD2 (0.49) | TGFBR1MAP3K20TGFBR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642265-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20050165007-A1 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165007-A1 | Benzimidazoles and analogs thereof as antivirals | ZC3HAV1, NXF1, ZC3HAV1L | TGFBR1 2293/4885MAP3K20 3704/4885TGFBR2 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.